Does the media favor IMCR or CMPX?

In the previous week, Compass Therapeutics had 2 more articles in the media than Immunocore. MarketBeat recorded 5 mentions for Compass Therapeutics and 3 mentions for Immunocore. Immunocore's average media sentiment score of 1.57 beat Compass Therapeutics' score of 0.60 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CMPX or KALV more profitable?

Compass Therapeutics' return on equity of -39.75% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -39.75% -35.29% KalVista Pharmaceuticals N/A -341.44% -111.94%

Is MAZE or CMPX more profitable?

Maze Therapeutics' return on equity of -36.62% beat Compass Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -36.62% -31.78% Compass Therapeutics N/A -39.75% -35.29%

Does the media favor MAZE or CMPX?

In the previous week, Maze Therapeutics had 2 more articles in the media than Compass Therapeutics. MarketBeat recorded 7 mentions for Maze Therapeutics and 5 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 0.60 beat Maze Therapeutics' score of 0.21 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CMPX or MLTX more profitable?

Compass Therapeutics' return on equity of -39.75% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Compass Therapeutics N/A -39.75% -35.29% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media prefer CMPX or MLTX?

In the previous week, MoonLake Immunotherapeutics had 12 more articles in the media than Compass Therapeutics. MarketBeat recorded 17 mentions for MoonLake Immunotherapeutics and 5 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 0.60 beat MoonLake Immunotherapeutics' score of 0.57 indicating that Compass Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 4 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, AVLN or CMPX?

Avalyn Pharma has higher earnings, but lower revenue than Compass Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A Compass Therapeutics $850K 440.69 -$66.49M -$0.41 N/A

Is AVLN or CMPX more profitable?

Avalyn Pharma's return on equity of 0.00% beat Compass Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Compass Therapeutics N/A -39.75% -35.29%

Does the media favor AVLN or CMPX?

In the previous week, Compass Therapeutics had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for Compass Therapeutics and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.82 beat Compass Therapeutics' score of 0.60 indicating that Avalyn Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Compass Therapeutics (CMPX) Competitors

$2.08 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$2.08 +0.00 (+0.19%)

As of 07:01 AM Eastern

Compare

CMPX vs. IMCR, KALV, MAZE, MLTX, and AVLN

Should you buy Compass Therapeutics stock or one of its competitors? MarketBeat compares Compass Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compass Therapeutics include Immunocore (IMCR), KalVista Pharmaceuticals (KALV), Maze Therapeutics (MAZE), MoonLake Immunotherapeutics (MLTX), and Avalyn Pharma (AVLN). These companies are all part of the "pharmaceutical products" industry.

How does Compass Therapeutics compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Compass Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Compass Therapeutics	N/A	-39.75%	-35.29%

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immunocore has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Immunocore currently has a consensus target price of $56.71, indicating a potential upside of 83.66%. Compass Therapeutics has a consensus target price of $12.91, indicating a potential upside of 520.63%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Immunocore has higher revenue and earnings than Compass Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.93	-$35.51M	-$0.55	N/A
Compass Therapeutics	$850K	440.69	-$66.49M	-$0.41	N/A

In the previous week, Compass Therapeutics had 2 more articles in the media than Immunocore. MarketBeat recorded 5 mentions for Compass Therapeutics and 3 mentions for Immunocore. Immunocore's average media sentiment score of 1.57 beat Compass Therapeutics' score of 0.60 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Compass Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Therapeutics beats Immunocore on 10 of the 16 factors compared between the two stocks.

How does Compass Therapeutics compare to KalVista Pharmaceuticals?

Compass Therapeutics (NASDAQ:CMPX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Compass Therapeutics has higher earnings, but lower revenue than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	440.69	-$66.49M	-$0.41	N/A
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

Compass Therapeutics' return on equity of -39.75% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Compass Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Compass Therapeutics presently has a consensus price target of $12.91, indicating a potential upside of 520.63%. KalVista Pharmaceuticals has a consensus price target of $30.60, indicating a potential upside of 13.33%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

68.4% of Compass Therapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Compass Therapeutics had 5 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 5 mentions for Compass Therapeutics and 0 mentions for KalVista Pharmaceuticals. Compass Therapeutics' average media sentiment score of 0.60 beat KalVista Pharmaceuticals' score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Compass Therapeutics	Positive
KalVista Pharmaceuticals	Neutral

Summary

Compass Therapeutics beats KalVista Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

How does Compass Therapeutics compare to Maze Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Maze Therapeutics has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Maze Therapeutics' return on equity of -36.62% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Compass Therapeutics	N/A	-39.75%	-35.29%

Compass Therapeutics has lower revenue, but higher earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	9.39	-$131.12M	-$2.53	N/A
Compass Therapeutics	$850K	440.69	-$66.49M	-$0.41	N/A

In the previous week, Maze Therapeutics had 2 more articles in the media than Compass Therapeutics. MarketBeat recorded 7 mentions for Maze Therapeutics and 5 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 0.60 beat Maze Therapeutics' score of 0.21 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maze Therapeutics currently has a consensus target price of $66.00, indicating a potential upside of 132.15%. Compass Therapeutics has a consensus target price of $12.91, indicating a potential upside of 520.63%. Given Compass Therapeutics' higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

68.4% of Compass Therapeutics shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Compass Therapeutics beats Maze Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Compass Therapeutics compare to MoonLake Immunotherapeutics?

Compass Therapeutics (NASDAQ:CMPX) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Compass Therapeutics' return on equity of -39.75% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Compass Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by insiders. Comparatively, 12.1% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Compass Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	440.69	-$66.49M	-$0.41	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Compass Therapeutics presently has a consensus price target of $12.91, indicating a potential upside of 520.63%. MoonLake Immunotherapeutics has a consensus price target of $23.85, indicating a potential upside of 19.83%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Compass Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

In the previous week, MoonLake Immunotherapeutics had 12 more articles in the media than Compass Therapeutics. MarketBeat recorded 17 mentions for MoonLake Immunotherapeutics and 5 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 0.60 beat MoonLake Immunotherapeutics' score of 0.57 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	4 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compass Therapeutics beats MoonLake Immunotherapeutics on 12 of the 15 factors compared between the two stocks.

How does Compass Therapeutics compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

In the previous week, Compass Therapeutics had 2 more articles in the media than Avalyn Pharma. MarketBeat recorded 5 mentions for Compass Therapeutics and 3 mentions for Avalyn Pharma. Avalyn Pharma's average media sentiment score of 0.82 beat Compass Therapeutics' score of 0.60 indicating that Avalyn Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma currently has a consensus price target of $59.00, indicating a potential upside of 92.12%. Compass Therapeutics has a consensus price target of $12.91, indicating a potential upside of 520.63%. Given Compass Therapeutics' higher possible upside, analysts plainly believe Compass Therapeutics is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

68.4% of Compass Therapeutics shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Avalyn Pharma has higher earnings, but lower revenue than Compass Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
Compass Therapeutics	$850K	440.69	-$66.49M	-$0.41	N/A

Avalyn Pharma's return on equity of 0.00% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Compass Therapeutics	N/A	-39.75%	-35.29%

Summary

Compass Therapeutics beats Avalyn Pharma on 6 of the 11 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPX vs. The Competition

Export

Metric	Compass Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$374.59M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-5.07	21.75	25.89	24.17
Price / Sales	440.69	336.15	545.01	100.37
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	1.87	8.31	10.75	6.38
Net Income	-$66.49M	$23.92M	$3.58B	$337.00M
7 Day Performance	-0.95%	1.93%	1.90%	-0.23%
1 Month Performance	-12.61%	-0.41%	-0.26%	-1.40%
1 Year Performance	-18.75%	65.22%	34.39%	27.76%

Compass Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPX Compass Therapeutics	3.5254 of 5 stars	$2.08 flat	$12.91 +520.6%	-18.8%	$374.59M	$850K	N/A	20	News Coverage Negative News High Trading Volume
IMCR Immunocore	3.1458 of 5 stars	$29.35 +2.6%	$56.71 +93.2%	-0.8%	$1.45B	$400.02M	N/A	320	Positive News High Trading Volume
KALV KalVista Pharmaceuticals	2.1665 of 5 stars	$27.00 flat	$30.60 +13.3%	N/A	$1.44B	$1.43M	N/A	100
MAZE Maze Therapeutics	2.3229 of 5 stars	$25.57 -0.4%	$66.00 +158.1%	+134.4%	$1.42B	$167.50M	N/A	121	Gap Down
MLTX MoonLake Immunotherapeutics	2.7244 of 5 stars	$22.16 +15.4%	$23.85 +7.6%	-58.1%	$1.41B	N/A	N/A	2	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPX) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Therapeutics (CMPX) Competitors

CMPX vs. IMCR, KALV, MAZE, MLTX, and AVLN

How does Compass Therapeutics compare to Immunocore?

Summary

How does Compass Therapeutics compare to KalVista Pharmaceuticals?

Summary

How does Compass Therapeutics compare to Maze Therapeutics?

Summary

How does Compass Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Compass Therapeutics compare to Avalyn Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Therapeutics (CMPX) Competitors

CMPX vs. IMCR, KALV, MAZE, MLTX, and AVLN

How does Compass Therapeutics compare to Immunocore?

Is IMCR or CMPX more profitable?

Do institutionals and insiders hold more shares of IMCR or CMPX?

Which has more risk & volatility, IMCR or CMPX?

Do analysts prefer IMCR or CMPX?

Which has preferable valuation & earnings, IMCR or CMPX?

Does the media favor IMCR or CMPX?

Summary

How does Compass Therapeutics compare to KalVista Pharmaceuticals?

Which has stronger earnings and valuation, CMPX or KALV?

Is CMPX or KALV more profitable?

Which has more volatility and risk, CMPX or KALV?

Do analysts rate CMPX or KALV?

Do institutionals and insiders have more ownership in CMPX or KALV?

Does the media favor CMPX or KALV?

Summary

How does Compass Therapeutics compare to Maze Therapeutics?

Which has more risk & volatility, MAZE or CMPX?

Is MAZE or CMPX more profitable?

Which has higher valuation and earnings, MAZE or CMPX?

Does the media favor MAZE or CMPX?

Do analysts rate MAZE or CMPX?

Do insiders and institutionals have more ownership in MAZE or CMPX?

Summary

How does Compass Therapeutics compare to MoonLake Immunotherapeutics?

Is CMPX or MLTX more profitable?

Which has more risk & volatility, CMPX or MLTX?

Do institutionals and insiders believe in CMPX or MLTX?

Which has preferable valuation & earnings, CMPX or MLTX?

Do analysts prefer CMPX or MLTX?

Does the media prefer CMPX or MLTX?

Summary

How does Compass Therapeutics compare to Avalyn Pharma?

Does the media favor AVLN or CMPX?

Do analysts rate AVLN or CMPX?

Do insiders & institutionals have more ownership in AVLN or CMPX?

Which has preferable earnings & valuation, AVLN or CMPX?

Is AVLN or CMPX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX vs. The Competition

Compass Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools